[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cornea-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cornea-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,60,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100626400","a-single-center-clinical-study-to-evaluate-the-efficacy-and-safety-of-autologous-urine-derived-epithelial-cells-in-the-treatment-of-corneal-endothelial-cell-dysfunction-100626400",false,"NCT07435142","A Single-Center Clinical Study to Evaluate the Efficacy and Safety of Autologous Urine-Derived Epithelial Cells in the Treatment of Corneal Endothelial Cell Dysfunction","Inclusion Criteria:\n\n1. Patients diagnosed with corneal endothelial cell dysfunction, including those with a history of at least one penetrating keratoplasty.\n2. Patients aged 18 years or older and 85 years or younger at the time of informed consent acquisition (regardless of gender).\n3. Patients with central corneal endothelial cell density below 500-800 cells\u002Fmm² or unmeasurable, as detected by corneal endothelial microscopy or confocal microscopy.\n4. Patients who can voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with unexplained keratoconjunctival diseases.\n2. Patients with active corneal infections or systemic infections (e.g., positive for bacteria, fungi, HBV, HCV, or other viruses).\n3. Patients with an intraocular pressure (IOP) of ≥30 mmHg (excluding those whose IOP can be controlled below 21 mmHg with glaucoma medications).\n4. Patients with neovascularization observed in the angle of the anterior chamber or who have undergone treatment for neovascular glaucoma.\n5. Patients with a history of allergies to drugs prescribed during the perioperative period and postoperative observation period \\[anesthetics (lidocaine injection), antibiotics (ofloxacin eye drops or ointment), steroid preparations (0.1% fluorometholone eye drops, tobramycin and dexamethasone eye drops or ointment, prednisolone acetate eye drops or ointment), glaucoma medications (prostaglandin preparations, β-blockers, carbonic anhydrase inhibitors, linezolid eye drops), etc.\\].\n6. Patients planning to undergo intraocular surgery during this clinical study.\n7. Diabetic patients with poor blood glucose control (HbA1C ≥8.5%).\n8. Patients with a history of cancer or\u002Fand with systemic autoimmune disease.\n9. Patients with severe liver dysfunction (AST\\>100 IU\u002FL or ALT\\>100 IU\u002FL).\n10. Patients with severe renal dysfunction requiring dialysis (serum creatinine ≥1.5 mg\u002Fdl).\n11. Patients with a systolic blood pressure of ≥180 mmHg or diastolic blood pressure of ≥110 mmHg despite antihypertensive treatment.\n12. Pregnant women, women possibly pregnant, or women planning pregnancy during this clinical study period.\n13. Patients unable to tolerate ophthalmic surgery under local anesthesia (e.g., severe claustrophobia).\n14. Patients who participated in other clinical trials or studies within 3 month prior to consent acquisition.\n15. Patients deemed unsuitable for this clinical study due to comorbidities, etc.","ALL","18 Years","85 Years",{"count":19,"type":20},3,"ESTIMATED","INTERVENTIONAL",[23],"NA","Corneal endothelial cell dysfunction is usually a corneal disease caused by damage or loss of corneal endothelial cells. It is characterized by corneal edema, opacity, and subepithelial bullae, leading to pain, blurred vision, or even blindness. Conventional treatments usually involve allogeneic corneal transplantation or corneal endothelial transplantation. Anterior chamber cell transplantation is a breakthrough treatment for corneal endothelial diseases developed in recent years. Autologous urine-derived epithelial cells greatly reduce the risk of immune rejection and the use of anti-rejection drugs, avoiding reliance on and waiting for corneal donors.",[26],"Cornea Disease","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2026-02-21",{"date":35,"type":20},"2026-11-01",{"name":37,"class":38},"Suxia Li","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":39},"100639690","a-single-center-clinical-study-to-evaluate-the-efficacy-and-safety-of-a-suture-free-ophthalmic-hydrogel-for-ocular-surface-tissue-adhesion-100639690","NCT07608367","A Single-Center Clinical Study to Evaluate the Efficacy and Safety of a Suture-Free Ophthalmic Hydrogel for Ocular Surface Tissue Adhesion","Inclusion Criteria:\n\n1. Patients with ocular surface diseases (e.g., pterygium, corneal ulcer, ocular surface burn, pseudopterygium, etc.) who need to undergo conjunctival flap adhesion, amniotic membrane transplantation, or keratoplasty.\n2. Aged 18 to 85 years old at the time of informed consent (regardless of gender).\n3. Able to provide written informed consent and voluntarily participate in the study.\n4. No severe systemic organic diseases, such as severe heart, liver, kidney diseases, and malignant tumors.\n\nExclusion Criteria:\n\n1. A history of allergy to the components of the suture-free ophthalmic hydrogel (e.g., decellularized porcine corneal matrix, GelMA, etc.) or the drugs prescribed during the perioperative and postoperative observation periods (anesthetics, antibiotics, steroid preparations, etc.).\n2. Patients with systemic infectious diseases (bacterial, fungal, positive for HBV, HCV and other viruses, etc.).\n3. Diabetic patients with poor blood glucose control (HbA1C ≥ 8.0%).\n4. Pregnant women, women who may be pregnant, or women planning to become pregnant during the clinical study.\n5. Patients who have participated in other clinical trials or studies within 1 month before obtaining informed consent.\n6. Other patients deemed unsuitable for the clinical study due to comorbidities.",{"count":47,"type":20},20,[23],"When severe ocular surface lesions occur (e.g., pterygium, corneal ulcer, ocular surface burn, etc.), the currently clinically common surgical procedures such as conjunctival flap coverage, amniotic membrane transplantation, and keratoplasty are primarily fixed by suturing. However, suturing has numerous drawbacks. On the one hand, the suturing process causes additional mechanical damage to ocular surface tissues, triggers local inflammatory responses, and increases postoperative discomfort such as pain and foreign body sensation. Moreover, uneven suture tension is prone to cause conjunctival flap shrinkage or displacement, impairing the repair effect. On the other hand, postoperative suture irritation continuously activates fibroblast proliferation, leading to excessive deposition of subconjunctival collagen and the formation of dense scar tissue, which in turn compromises the stability of the ocular surface tear film and visual quality. This study intends to develop a suture-free ophthalmic hydrogel for conjunctival flap adhesion. By combining the natural biological activity of decellularized porcine corneal matrix with the photocrosslinking properties of GelMA, and integrating low-energy visible light (465nm) curing technology, the hydrogel enables rapid, firm, and suture-free adhesion of conjunctival flaps.",[26],"NOT_YET_RECRUITING","2026-05-20",{"date":54,"type":31},"2026-05-27",{"date":56,"type":20},"2026-05-22",{"date":58,"type":20},"2027-06-01",{"name":37,"class":38},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":39},"100380391","the-role-of-transscleral-cyclophotocoagulation-in-patients-undergoing-a-boston-keratoprosthesis-100380391","NCT04232982","The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis","Inclusion Criteria:\n\n* Adults patients\n* Able to give an informed consent\n* Capable of being followed during the study\n* Candidate for the Boston keratoprosthesis type I\n\nExclusion Criteria:\n\n* Patients younger than 18 years old or older than 80 years old\n* Unable to give an informed consent\n* Participating to another interventional glaucoma study\n* Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit.\n* Unable to wear a therapeutic contact lens secondary to eyelid malformation\n* Severe Ocular surface Disease with keratinization\n* Intra-ocular tumor\n* Terminal Glaucoma\n* Phthisis bulbi\n* Ocular albinism","80 Years",{"count":47,"type":20},[23],"The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success.\n\nGlaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure.\n\nIn order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye.\n\nThe transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis.\n\nOur hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis .\n\nMETHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist.\n\nFollowing their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.",[71,72,26],"Glaucoma","Eye Diseases",[74,75,76,77],"Boston keratoprosthesis","Transscleral cyclophotocoagulation","Micropulse transscleral cyclophotocoagulation","G-Probe Transscleral cyclophotocoagulation","2026-04-23",{"date":80,"type":31},"2026-04-27",{"date":82,"type":31},"2020-01-30",{"date":84,"type":20},"2036-12-01",{"name":86,"class":38},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":39},"100562279","phase-3-effects-of-topical-insulin-on-corneal-epithelium-healing-after-corneal-crosslinking-in-patients-with-keratoconus-100562279","NCT06601101","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of keratoconus, indicated for corneal crosslinking\n\nExclusion Criteria:\n\n* Diabetes Mellitus\n* Severe dry eye\n* Limbal Stem Cell Deficiency\n* Glaucoma\n* Insulin or methylcellulose allergy","14 Years",{"count":96,"type":20},36,[98],"PHASE3","The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project. The objective of this study is to evaluate the effect of insulin eye drops at a concentration of 50 IU\u002Fml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial will be conducted with two groups, one being the control group, in which researchers will compare the epithelial healing rate in mm²\u002Fh between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure, will be invited to participate. As a result of the study, it is expected to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo. Topical insulin may contribute to early epithelial defect closure, control of inflammation, and prevention of complications that could significantly impact visual quality.",[101,26,72,102],"Keratoconus","Wound Heal",[104,105],"Topical Insulin","Crosslinking","2025-01-10",{"date":108,"type":31},"2025-01-14",{"date":110,"type":31},"2024-08-01",{"date":112,"type":20},"2025-10-01",{"name":114,"class":38},"University of Campinas, Brazil"]